Advertisement
U.S. Markets closed

Aroa Biosurgery Limited (ARX.AX)

ASX - ASX Delayed Price. Currency in AUD
0.5850+0.0050 (+0.86%)
At close: 04:10PM AEDT

Aroa Biosurgery Limited

64 Richard Pearse Drive
Airport Oaks Mangere
Auckland 2022
New Zealand
64 9 869 3035
https://aroa.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Brian Ward B.V.Sc, MBA(dist)Founder, CEO, MD & Executive Director611.89kN/AN/A
Mr. James Agnew BCom, LLBCFO & Joint Company Secretary350.63kN/AN/A
Mr. Rod Stanley M.Sc.Chief Technology OfficerN/AN/AN/A
Dr. Barnaby C.H. May Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Neetha Alex-KumarGeneral CounselN/AN/AN/A
Mr. Frazer MurrayDirector of Global Marketing & StrategyN/AN/AN/A
Ms. Yasmin Winchester B.Sc.Vice President of Quality, Regulatory & SustainabilityN/AN/AN/A
Ms. Tracy Weimar BA, MBAJoint Company SecretaryN/AN/AN/A
Mr. Adam Young Ph.D.Vice President of Medical AffairsN/AN/AN/A
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and OviTex and OviTex PRS, a reinforced bioscaffolds for use in hernia repair and abdominal wall reconstruction, as well as breast reconstruction. The company also offers Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.

Corporate Governance

Aroa Biosurgery Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.